The Biopharmaceutical Company focused on the biology of healing has announced a fundraising via a bought deal, at C$3.1 per share, to raise a minimum of C$60m in gross proceeds. Combined with the March $30m follow on financing by Thomvest, this provides ProMetic with significant firepower to progress and expand its rapidly accelerating clinical program and broaden its manufacturing capabilities related to plasma derived therapeutics. Our updated forecasts now project a year end cash balance o
09 May 2016
Clinical strength now matched by balance sheet strength
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Clinical strength now matched by balance sheet strength
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
09 May 2016 -
Author:
Derren Nathan -
Pages:
7
The Biopharmaceutical Company focused on the biology of healing has announced a fundraising via a bought deal, at C$3.1 per share, to raise a minimum of C$60m in gross proceeds. Combined with the March $30m follow on financing by Thomvest, this provides ProMetic with significant firepower to progress and expand its rapidly accelerating clinical program and broaden its manufacturing capabilities related to plasma derived therapeutics. Our updated forecasts now project a year end cash balance o